Posaconazol: Ein weiteres Triazol-Antimykotikum der neuen Generation?

Schlüsselwörter

Posaconazol - Triazolantimykotikum - Hämato-Onkologie - Lanosterol-14α-Demethylase - Cytochrom-P₄₅₀-Enzyme - Pharmakokinetik - Arzneimittelinteraktionen

Keywords

Posaconazole - triazole antifungal drug - hemato-oncology - lanosterol-14α-demethylase - cytochrome-P₄₅₀-enzyme - pharmacokinetics - drug-drug-interactions

Literatur

• 1 Aktories F. et al .Allgemeine und spezielle Pharmakologie und Toxikologie. München; Urban & Fischer 2005
• 2 Cornely O A. et al . Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.  N Engl J Med. 2007;  356 348-359
• 3 Fachinformation zu Noxafil® SEB. 2007, Oktober
• 4 Hof H. A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity.  Mycoses. 2006;  49 Suppl 1 2-6
• 5 Keating G M. Posaconazole.  Drugs. 2005;  65 1553-1567; discussion 1568 – 1559
• 6 Muller C. et al . HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases.  Mycoses. 2006;  49 Suppl 1 17-22
• 7 Pitisuttithum P. et al . Activity of posaconazole in the treatment of central nervous system fungal infections.  J Antimicrob Chemother. 2005;  56 745-755
• 8 Raad II. et al . Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.  Clin Infect Dis. 2006;  42 1726-1734
• 9 Raad II. et al . Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.  Leukemia. 2008;  22 496-503
• 10 Smith J. et al . Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations.  Ther Drug Monit. 2008;  30 167-172
• 11 Ullmann A J. et al . Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.  Antimicrob Agents Chemother. 2006;  50 658-666
• 12 Ullmann A J. et al . Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.  N Engl J Med. 2007;  356 335-347
• 13 Walsh T J. et al . Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.  Clin Infect Dis. 2007;  44 2-12
• 14 Wexler D. et al . Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study.  Eur J Pharm Sci. 2004;  21 645-653